Founded in 1985, the University of Pittsburgh Cancer Institute (UPCI) is the only National Cancer Institute (NCI)-designated Comprehensive Cancer Center in western Pennsylvania. With more than 350 research and clinical faculty members specializing in disciplines ranging from cancer prevention and early detection to novel therapeutic discovery, survivorship, and end of life care, UPCI maintains a broad strategic vision and comprehensive approach to understanding and defeating cancer. In 2011, UPCI received nearly $174 million in research grants, and was ranked 12th nationally in funding from the National Cancer Institute.
UPCI investigators are leaders in molecular and medical oncology, spearheading innovative research studies to:
- Advance our understanding of the biological basis of cancer development and progression
- Identify new and relevant biomarkers for improved cancer detection and diagnosis
- Develop novel therapeutics for successful and comprehensive cancer treatment
- Establish and implement effective measures for cancer prevention
While most UPCI faculty maintain academic appointments at the University of Pittsburgh, some UPCI members are affiliated with neighboring institutions, including Carnegie Mellon University and University of Pittsburgh Medical Center (UPMC) Hospitals.
At UPCI, basic researchers collaborate with clinician-scientists to rapidly advance the most promising laboratory studies into novel clinical trials, providing patients with early access to new and innovative treatments both at the Hillman Cancer Center and throughout the network of UPMC CancerCenter sites. Currently, patients have access to hundreds of clinical trials at UPCI and UPMC CancerCenter.
Sustained by the ongoing recruitment of internationally renowned scientists, increases in funding, and planned expansion of laboratory and clinical space, UPCI continues to grow and evolve, making vast strides in its quest to significantly reduce the burden of cancer.